Influenza Vaccine Program Summary, 2018 – 2019 Influenza Season

(FLU)

Biological	Indications	Initial Series	Specific Contraindications	Expected Reactions
Quadrivalent Influenza vaccine (QIV) (Split virion, inactivated) **A/Michigan**/45/2015)(H1N1) pdm09-like strain **A/Singapore**/INFIMH-16-0019/2016 (H3N2)-like strain **B/Phuket**/3073/2013–like strain **B/Colorado**/6/2017- like strain **Manufacturers:** Fluzone® (Sanofi Pasteur) • MDV & PFS FLULAVAL TETRA (GlaxoSmithKline) • MDV Licensed for: individuals 6 months of age and older **Goals:** 80% ≥ 65 years of age 80% 6 – 23 months of age 80% of health care workers 100% of immunizers	**Universal Program for anyone 6 months of age and older who lives, works or studies in Alberta.** **People at high risk of influenza-related complications or hospitalization:** • Anyone 65 years of age and older. • Children 6 – 59 months of age • Pregnant women at any stage of pregnancy and lactating women. • Indigenous peoples • Adults and children with the following health conditions: ▪ Chronic cardiac ▪ Chronic respiratory (including asthma) ▪ Immunosuppression/ immunodeficiency/HIV ▪ Diabetics/other metabolic diseases ▪ Cancer ▪ Renal disease ▪ Anemia ▪ Cognitive dysfunction, spinal cord injury, seizure disorder, neuromuscular disorder • Children 6 months to 18 years of age on long term ASA therapy • Neurologic or neurodevelopment conditions • Morbid obesity (BMI ≥ 40) **People capable of transmitting influenza to those at risk:** ▪ Health care workers ▪ All household contacts of high risk individuals ▪ Members of household expecting a newborn ▪ Regular child caregivers for children ≤ 59 months of age. **Others:** ▪ People who provide essential community services ▪ People in direct contact during culling operations with poultry infected with avian influenza ▪ Health individuals aged 5 – 64 years ▪ Travelers	**Individuals 6 months up to and including 8 years of age who HAVE NOT received influenza vaccine in a previous season:** ▪ 2 doses, 4 weeks apart (*document: 1 of 2, 2 of 2)* **Individuals 6 months up to and including 8 years of age who HAVE received influenza vaccine in a previous season:** ▪ 1 dose (document: Annual) **Individuals 9 years of age and older:** ▪ 1 dose **Dose:** 0.5 ml IM **Minimum age:** 6 months of age **Maximum age:** no limit **Notes:** • A reason code must be documented for each dose administered; do NOT leave blank or use "unknown" • Influenza vaccine status/eligibility should be assessed during routine contact: ▪ Well-child clinics (everyone with child) ▪ Seniors clinics ▪ Diabetes events ▪ Prenatal/postnatal classes ▪ Etc. • May be given at the same time as other inactivated and live vaccines using a separate needle and syringe for each vaccine.	• Infants under 6 months of age • Anaphylactic reaction to a previous dose of influenza vaccine or to any constituent of the vaccine • severe ORS following previous doses of influenza vaccine *(See ORS Algorithm)* • Individuals who developed GBS within 6 weeks of previous influenza immunization. • Individuals with acute, febrile illness should be deferred until better. **Note:** Egg allergy is **NOT** a contraindication to inactivated influenza immunization. Individuals severely allergic to eggs should be monitored for 30 minutes following immunization.	**Common:** ▪ Injection site pain, tenderness, redness, swelling ▪ Irritability, abnormal crying, malaise, fatigue, anorexia, myalgia, headache, fever, dizziness, gastrointestinal symptoms, arthralgia **Rare:** ▪ Anaphylaxis, allergic reaction ▪ Oculo-respiratory syndrome ▪ Guillain-Barré Syndrome ▪ As with any immunization, unexpected or unusual side effects can occur.

Note:

- Fluzone® and FLULVAL TETRA multidose vials: once entered can use for 28 days if sterile technique and cold chain maintained.
- Protect from light. Do not inject intradermally, subcutaneously or intravenously.
- Cold Chain must be strictly observed.

- QIV: Quadrivalent influenza vaccine.